ArticleNature immunology2021
The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination.
Open access · bronzeAbstract read
In one paragraph
Article in Nature immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 24 citations in OpenAlex.
- Trial
- Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk.The Journal of infectious diseases · 2022Trial
- Arbutin as a promising cardioprotective anticancer adjuvant with doxorubicin in solid Ehrlich carcinoma through targeting NEK7-dependent inflammasome/SIRT1/caspase-3/oxidative stress pathways.Molecular and cellular biochemistry · 2026Article
- Host Genetic Regulation of NLRP3 Inflammasome Cytokines Reveals Immune and Vascular Pathways in HIV.medRxiv : the preprint server for health sciences · 2026Article
- Review
- Poxvirus infection triggers remodeling of host m⁶A epitranscriptome and benefits from the m⁶A regulatory responses.Virology journal · 2026Article
- A pre-vaccination immune metabolic interplay determines the protective antibody response to a dengue virus vaccine.Cell reports · 2024Article
- Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects.Viruses · 2024Review
- In Vivo Treatment with Insulin-like Growth Factor 1 Reduces CCR5 Expression on Vaccine-Induced Activated CD4Vaccines · 2023Article
- Next-Generation Adjuvants: Applying Engineering Methods to Create and Evaluate Novel Immunological Responses.Pharmaceutics · 2023Article
- ALVAC-HIV and AIDSVAX B/E vaccination induce improved immune responses compared with AIDSVAX B/E vaccination alone.JCI insight · 2023Article
- Vaccine plus microbicide effective in preventing vaginal SIV transmission in macaques.Nature microbiology · 2023Article
- HIV vaccine candidate efficacy in female macaques mediated by cAMP-dependent efferocytosis and V2-specific ADCC.Nature communications · 2023Article
- Article
- Species-specific transcriptomic changes upon respiratory syncytial virus infection in cotton rats.Scientific reports · 2022Article
- Lysophosphatidic Acid Is a Proinflammatory Stimulus of Renal Tubular Epithelial Cells.International journal of molecular sciences · 2022Article
- Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses.Journal of virology · 2022Review
- Long-term and potent IOP-lowering effect of IκBα-siRNA in a nonhuman primate model of chronic ocular hypertension.iScience · 2022Article
- Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses.Nature immunology · 2022Review
- Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines.Current opinion in virology · 2022Review
Corrections and comments
- Commented on by
Authors and funding
23 authors at 8 institutions in 1 country.
Jeffrey Alan TomalkaDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Adam Nicolas PelletierDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Slim FouratiDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.ORCID http://orcid.org/0000-0001-6609-7587
Muhammad Bilal LatifDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Ashish SharmaPathology Advanced Translational Research Unit, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Kathryn FurrCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Kevin CarlsonCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Michelle LiftonCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0279-2198
Ana GonzalezCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Peter WilkinsonDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Genoveffa FranchiniCenter for Cancer Research Vaccine Branch, National Cancer Institute NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-2851-6589
Robert ParksDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Norman LetvinCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Nicole YatesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Kelly SeatonDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.ORCID http://orcid.org/0000-0002-2009-3270
Georgia TomarasDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Jim TartagliaSanofi-Pasteur, Swiftwater, PA, USA.
Merlin L RobbMilitary HIV Research Program, Henry Jackson Foundation and Walter Reed Army Institute for Research, Bethesda and Silver Spring, MD, USA.ORCID http://orcid.org/0000-0003-3949-9649
Nelson L MichaelMilitary HIV Research Program, Henry Jackson Foundation and Walter Reed Army Institute for Research, Bethesda and Silver Spring, MD, USA.
Richard KoupVaccine Research Center, National Institutes of Health, Bethesda, MD, USA.
Barton HaynesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Sampa SantraCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. ssantra@bidmc.harvard.edu.ORCID http://orcid.org/0000-0002-8796-1714
Rafick Pierre SekalyDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA. rafick.sekaly@emory.edu.
Beth Israel Deaconess Medical Center · USDuke University · USEmory University · USJackson Foundation · USUniversity School · USNational Cancer Institute · USNational Institutes of Health · USSanofi (United States) · US
Funding
Viral Sequencing CoreU19AI067854 · NIAID · DUKE UNIVERSITY · PI BHARDWAJ, NINA · 2006 to 2011
$290.5MVirus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MCMICHAEL, ANDREW JAMES · 2012 to 2018
$204.7MNonhuman primate studies for development of a prototype HIV vaccine that induces broadly neutralizing antibodiesUM1AI144371 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2019 to 2025
$190.4MYerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MThe impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4MNew England Primate Research Center Base GrantP51OD011103 · OD · HARVARD MEDICAL SCHOOL · PI FLIER, JEFFREY S · 2012 to 2013
$24.7MViral and Host Determinants of HIV-1 TransmissionU01AI067854 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F · 2005 to 2005
$14.9MIllumina NovaSeq 6000 High Throughput DNA Sequencer for Emory UniversityS10OD026799 · OD · EMORY UNIVERSITY · PI BOSINGER, STEVEN EDWARD · 2019 to 2019
$985kNIAID NIH HHS P30 AI060354NIAID NIH HHS U01 AI067854NIAID NIH HHS U19 AI067854NIAID NIH HHS UM1 AI100645NIAID NIH HHS UM1 AI144371NIH HHS P51 OD011103NIH HHS P51 OD011132NIH HHS S10 OD026799
Abstract
Development of effective human immunodeficiency virus 1 (HIV-1) vaccines requires synergy between innate and adaptive immune cells. Here we show that induction of the transcription factor CREB1 and its target genes by the recombinant canarypox vector ALVAC + Alum augments immunogenicity in non-human primates (NHPs) and predicts reduced HIV-1 acquisition in the RV144 trial. These target genes include those encoding cytokines/chemokines associated with heightened protection from simian immunodeficiency virus challenge in NHPs. Expression of CREB1 target genes probably results from direct cGAMP (STING agonist)-modulated p-CREB1 activity that drives the recruitment of CD4
Indexed as
Adjuvants, ImmunologicAIDS VaccinesAnimalsB-LymphocytesCD4-Positive T-LymphocytesCyclic AMP Response Element-Binding ProteinGene ExpressionGenetic VectorsHIV-1HIV AntibodiesHIV InfectionsHumansImmunizationImmunogenicity, VaccinePrimatesVaccinationAdjuvants, ImmunologicAIDS VaccinesALVAC vaccineCyclic AMP Response Element-Binding ProteinHIV AntibodiesViral Vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.